Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022. The reports are available at the SEC's website,, as well as on

Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. For more information, visit, Facebook, Instagram, X, LinkedIn and YouTube.

Contact for further information

Ambre James-Brown +45 3079 Elizabeth DeLuca (US)+1 609 580
Daniel Muusmann Bohsen+45 3075 2175 Jacob Martin Wiborg Rode+45 3075
David Heiberg Landsted +45 3077 6915 Mark Joseph Root (US) +1 848 213
Sina Meyer +45 3079 Frederik Taylor Pitter +45 3075


  • PR240131-SEC-filing
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Novo Nordisk Charts.